查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1736717

全球输血诊断市场：市场规模（按组件、应用、最终用户和地区划分）、未来预测

Global Blood Transfusion Diagnostics Market Size By Component (Reagents & Kits, Instruments), By Application (Blood Grouping, Disease Screening), By End-User (Blood Banks, Hospitals), By Geographic Scope and Forecast
出版日期: | 出版商: Verified Market Research | 英文 | 商品交期: 2-3个工作天内

价格
简介目录

输血诊断市场规模及预测

2024 年输血诊断市场规模价值 56.4 亿美元，预计到 2032 年将达到 103.3 亿美元，2026 年至 2032 年的复合年增长率为 7.86%。

输血诊断包括几个重要的检测和程序，旨在确保输血的安全性和相容性。这些检测有助于确定供血者和受血者的血型是否匹配，从而降低致命输血反应的风险。重要的检测包括血型鑑定（用于识别ABO血型和Rh血型）以及交叉配血（用于确认供血者和受血者的血型是否相容）。

这些检测对于确保输血的安全性和有效性至关重要，尤其是血型鑑定、交叉配血和传染病检查。血型鑑定对于识别供血者和受血者的血型（ABO和Rh）以及预防输血相关併发症至关重要。交叉配血检测可以提高供血者和受血者的血液相容性，并降低出现问题的几率。

随着检测速度、准确性和安全性的技术进步，输血诊断的未来应用预计将持续发展。核酸检测 (NAT) 等分子诊断方法正日益普及，因为它们能够以较低剂量更早检测出病原体，从而提高输血安全性。

全球输血诊断市场动态

影响全球输血诊断市场的关键市场动态是：

关键市场驱动因素

输血需求不断增长：主要驱动因素之一是，随着慢性疾病、创伤、手术和急诊护理的日益普遍，输血需求也日益增长。癌症、心血管疾病和贫血等疾病通常需要反覆输血，这增加了对综合诊断技术的需求，以确保血液的安全性和相容性。

技术进步：诊断技术的创新正在推动市场扩张。自动化技术、核酸检测 (NAT) 和次世代定序的使用提高了血液检测的准确性、速度和可靠性。这些发展减少了人为错误，提高了血液传染疾病的检测率，并改善了血液相容性检测的结果，从而增加了对先进诊断设备的需求。

严格的安全法规：政府和卫生机构制定了严格的安全要求，以减少输血相关后果，例如溶血反应和感染疾病传播。这些要求要求对捐血血液进行彻底筛检，并要求使用最新的诊断设备，包括试剂、设备和软体，以确保合规。

主要挑战

严格的监管要求：输血诊断产品受到美国食品药物管理局 (FDA)、欧洲药品管理局 (EMA) 和其他国际监管机构等卫生部门的严格监管。这些法规要求进行广泛的临床试验和安全检验，这可能会延迟产品核准和上市。

诊断设备成本：先进的诊断设备，尤其是配备分子诊断和核酸检测等最尖端科技的设备，价格可能高得令人望而却步。这些成本可能令人望而却步，尤其对于中低收入国家的小型医疗机构而言。这些技术及其频繁使用所需试剂的价格限制了其广泛应用，并阻碍了资源匮乏地区的医疗服务。

供不应求：输血诊断的有效性取决于能否获得安全且相容的血液供应。然而，由于捐赠者短缺以及血液采集和储存方面的后勤挑战而导致的血液短缺可能会危及诊断过程。

主要趋势

技术进步：自动化分析仪和分子诊断等先进技术的引入正在改变输血诊断。自动化解决方案提高了血型鑑定和病原体检测的速度和准确性，减少了人为错误，并提高了实验室工作流程的效率。

血液成分需求不断增长：随着慢性疾病、外科手术和创伤的日益普遍，全球的输血需求也日益增长。这一趋势凸显了对有效输血诊断技术的需求，以确保血液製品的安全性和相容性。为了因应日益增长的输血需求，医疗专业人员越来越多地采用全面的检测标准。

法规合规性和安全标准：监管机构正在实施更严格的规定，以确保输血程序的安全性和有效性。这些要求需要全面的诊断检测，从而增加了对高品质试剂、套件和设备的需求。随着合规性要求日益严格，医疗机构正在投资可靠的诊断解决方案，以达到这些安全标准。

目录

第一章全球输血诊断市场简介

  • 市场概览
  • 分析范围
  • 先决条件

第二章执行摘要

第三章 已验证的市场研究分析方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球输血诊断市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球输血诊断市场（按组件）

  • 概述
  • 试剂和套件
  • 装置
  • 软体与服务

6. 全球输血诊断市场（按应用）

  • 概述
  • 血型分类
  • 疾病筛检

7. 全球输血诊断市场（依最终用户）

  • 血库
  • 医院
  • 诊断实验室

8. 全球输血诊断市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

9. 全球输血诊断市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十章 公司简介

  • Ortho clinical Diagnostics
  • DiaSorin Sp A
  • Abbott
  • Grifols
  • SA, F.
  • Hoffmann-La Roche Ltd
  • Bio-Rad Laboratories
  • Siemens Healthcare Private Limited
  • Thermo Fisher Scientific Inc.
  • Beckman Coulter, Inc

第十一章 附录

    • 相关分析
简介目录
Product Code: 40319

Blood Transfusion Diagnostics Market Size and Forecast

Blood Transfusion Diagnostics Market size was valued at USD 5.64 Billion in 2024 and is projected to reach USD 10.33 Billion by 2032, growing at a CAGR of 7.86% from 2026 to 2032.

Blood transfusion diagnostics include several key tests and procedures designed to assure the safety and compatibility of blood transfusions. These tests assist in determining the optimal match between donor and recipient blood types reducing the danger of potentially fatal transfusion reactions. The key tests are blood typing which identifies ABO and Rh blood groups and cross-matching which confirms compatibility between the donor's and recipient's blood.

These diagnostics are critical for guaranteeing the safety and efficacy of blood transfusions, particularly blood typing, cross-matching, and infectious disease testing. Blood typing is essential for identifying the donor and recipient's blood groups (ABO and Rh) and preventing transfusion-related complications. Cross-matching tests ensure greater compatibility between donor and recipient blood lowering the likelihood of problems.

The future usage of blood transfusion diagnostics is projected to evolve in tandem with technological advancements, improving testing speed, accuracy, and safety. Molecular diagnostics, such as nucleic acid testing (NAT), are gaining popularity allowing for earlier detection of pathogens at lower doses, hence enhancing transfusion safety.

Global Blood Transfusion Diagnostics Market Dynamics

The key market dynamics that are shaping the global blood transfusion diagnostics market include:

Key Market Drivers:

Rising Blood Transfusion Demand: One of the key factors is the increased need for blood transfusions as chronic diseases, trauma cases, surgeries, and emergency treatment become more common. Conditions such as cancer, cardiovascular disease, and anemia frequently necessitate repeated transfusions increasing the necessity for comprehensive diagnostic technologies to ensure blood safety and compatibility.

Technological Advancements: Innovations in diagnostic technology are driving market expansion. The use of automated technologies, nucleic acid testing (NAT), and next-generation sequencing has improved the accuracy, speed, and reliability of blood tests. These developments reduce human error, improve the detection of blood-borne diseases, and provide improved results in blood compatibility testing resulting in increased demand for advanced diagnostic instruments.

Stringent Safety Regulations: Governments and health organizations impose stringent safety requirements to reduce transfusion-related consequences such as hemolytic responses and the spread of infectious infections. These requirements require complete screening of donated blood necessitating the use of modern diagnostics such as reagents, devices, and software, to ensure compliance.

Key Challenges:

Stringent Regulatory Requirements: Blood transfusion diagnostics are subject to stringent regulatory requirements from health authorities such as the FDA, EMA, and other international regulatory bodies. These rules necessitate significant clinical investigations and safety validations which might delay product approval and market introduction.

Diagnostic Tool Costs: Advanced diagnostic equipment, particularly devices equipped with cutting-edge technology such as molecular diagnostics and nucleic acid testing can be prohibitively expensive. These expenses can be prohibitive for smaller healthcare facilities, especially in low- and middle-income nations. The price of these technologies and the reagents necessary for frequent use limits their widespread acceptance presenting barriers to access in resource-constrained places.

Blood Supply Shortages: The efficacy of blood transfusion diagnostics is contingent on the availability of safe and compatible blood supplies. However, blood shortages caused by insufficient donors or logistical challenges during collection and storage can risk the diagnostic process.

Key Trends:

Technological Advancements: The incorporation of sophisticated technology such as automated analyzers and molecular diagnostics is altering blood transfusion diagnosis. Automated solutions increase the speed and accuracy of blood typing and pathogen detection, lowering human error and increasing lab workflow efficiency.

Growing Demand for Blood Components: As chronic diseases, surgical operations, and trauma cases become more common, so does the demand for blood transfusions around the world. This trend emphasizes the need for effective blood transfusion diagnostics to assure safe and compatible blood products. Healthcare professionals are increasingly focused on comprehensive testing standards to manage the growing patient population that requires blood transfusions.

Regulatory Compliance and Safety Standards: Regulatory bodies are enforcing stronger rules to assure the safety and efficacy of blood transfusion procedures. These requirements require comprehensive diagnostic testing which increases the demand for high-quality reagents, kits, and instruments. As compliance requirements become increasingly stringent, healthcare facilities invest in dependable diagnostic solutions to achieve these safety standards.

Global Blood Transfusion Diagnostics Market Regional Analysis

Here is a more detailed regional analysis of the global blood transfusion diagnostics market:

North America:

The North American leads the blood transfusion diagnostics market due to its advanced healthcare infrastructure and high healthcare spending. Canada and Mexico both contribute significantly to market growth to a lesser level. The American Cancer Society estimates that 1.9 million new cancer cases will be identified in the United States in 2021 with many requiring blood transfusions during treatment.

According to the American Red Cross, the United States requires roughly 29,000 units of red blood cells every day. Another important driver is the increasing number of surgical procedures. The aging population also helps to drive market growth as older people are more likely to require blood transfusions. According to the United States Census Bureau, by 2030, all baby boomers will be over the age of 65, bringing the total elder population to 73 million people.

Blood transfusion diagnostics have improved in terms of safety and efficiency thanks to technological breakthroughs such as nucleic acid amplification testing (NAT). The FDA states that NAT can detect HIV 10 to 14 days sooner than previous antibody tests, considerably lowering the risk of transfusion-transmitted infections.

Asia Pacific:

The Asia Pacific blood transfusion diagnostics market is expanding rapidly with the area emerging as the fastest-growing market internationally. This acceleration is mostly due to the increasing population, rising prevalence of chronic diseases, and improved healthcare infrastructure in nations such as China and India. According to the World Health Organization, the prevalence of diabetes in the Western Pacific region, which includes many Asian countries, is anticipated to rise by 57%, from 131 million in 2021 to 206 million in 2045.

This growth in chronic diseases frequently needs blood transfusions, increasing the demand for diagnostic technologies. Furthermore, the growing number of surgical procedures in the region supports market expansion. According to World Bank data, current health expenditure per capita in East Asia and the Pacific has increased by 75%, from $571 in 2010 to $1,001 in 2019. This increased funding has resulted in better-equipped hospitals and blood banks accelerating the implementation of modern blood transfusion testing technology.

Furthermore, government attempts to improve blood safety are driving market expansion. For example, the National AIDS Control Organization (NACO) in India reported that HIV screening of given blood units has increased from 80% in 2007 to 100% in subsequent years, demonstrating the growing importance of blood safety procedures.

Global Blood Transfusion Diagnostics Market: Segmentation Analysis

The Global Blood Transfusion Diagnostics Market is segmented based on Component, Application, End-User, and Geography.

Blood Transfusion Diagnostics Market, By Component

  • Reagents & Kits
  • Instruments
  • Software & Services

Based on the Component, the Global Blood Transfusion Diagnostics Market is bifurcated into Reagents & Kits, Instruments, and Software & Services. Reagents & Kits dominate the global blood transfusion diagnostics market due to their essential role in conducting blood typing, disease screening, and cross-matching tests. These consumables are in constant demand as they are critical for every transfusion procedure regardless of the equipment used. Reagents & kits are used across various healthcare settings including hospitals, blood banks, and diagnostic laboratories ensuring consistent market demand. Additionally, the frequent use and shorter shelf life of reagents and kits drive repeat purchases further boosting their market dominance.

Blood Transfusion Diagnostics Market, By Application

  • Blood Grouping
  • Disease Screening

Based on the Application, the Global Blood Transfusion Diagnostics Market is bifurcated into Blood Grouping and Disease Screening. In the global blood transfusion diagnostics market, disease screening is the dominant application. This is primarily driven by the critical need to ensure the safety of blood transfusions by screening for infectious diseases such as HIV, hepatitis, syphilis, and others. With stringent safety regulations in place, disease screening has become a priority to prevent the transmission of infections through blood transfusions. Additionally, advancements in testing technologies such as nucleic acid testing (NAT) have enhanced the ability to detect pathogens with greater accuracy and speed.

Blood Transfusion Diagnostics Market, By End-User

  • Blood Banks
  • Hospitals
  • Diagnostic Laboratories

Based on the End-User, the Global Blood Transfusion Diagnostics Market is bifurcated into Blood Banks, Hospitals, and Diagnostic Laboratories. Hospitals are the dominant end-user in the blood transfusion diagnostics market due to their critical role in administering blood transfusions. Hospitals handle a wide range of medical conditions including surgeries, trauma care, and chronic diseases where blood transfusions are frequently required. As a result, they maintain a constant demand for accurate and timely blood transfusion diagnostics to ensure patient safety and effective treatment outcomes. Additionally, hospitals have integrated diagnostic facilities and blood banks that allow for seamless testing, cross-matching, and transfusion services.

Blood Transfusion Diagnostics Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the Global Blood Transfusion Diagnostics Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is the dominant region in the global blood transfusion diagnostics market primarily due to the well-established healthcare infrastructure and the high demand for advanced diagnostic technologies. The region's strong presence of major diagnostic companies such as Abbott Laboratories and Ortho Clinical Diagnostics, drives innovation and adoption of cutting-edge blood testing methods. Additionally, North America has a robust blood donation system and stringent regulations ensuring the safety of transfusions which boosts demand for accurate diagnostic tools. The increasing prevalence of chronic diseases, surgical procedures, and trauma cases further elevates the need for reliable blood transfusion diagnostics.

Key Players

The "Global Blood Transfusion Diagnostics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott Laboratories, Grifols, Bio-Rad Laboratories, Immucor, Ortho Clinical Diagnostics, Quotient Limited, Roche Diagnostics, Haemonetics, Terumo BCT, and Beckman Coulter.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Blood Transfusion Diagnostics Market Key Developments

  • In November 2023, Grifols announced the Grifols sCD38 solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients.
  • In March 2022, Mylab Discovery Solutions Pvt. Ltd. launched the NATSpert ID tripleH detection kit, san RT-PCR test that detects infection in given blood.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY COMPONENT

  • 5.1 Overview
  • 5.2 Reagents & Kits
  • 5.3 Instruments
  • 5.4 Software & Services

6 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY APPLICATIONS

  • 6.1 Overview
  • 6.2 Blood Grouping
  • 6.3 Disease Screening

7 BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY END-USER

  • 7.1 Blood Banks
  • 7.2 Hospitals
  • 7.3 Diagnostic Laboratories

8 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Ortho clinical Diagnostics
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 DiaSorin S.p. A
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Abbott
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Grifols
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 S.A., F.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Hoffmann-La Roche Ltd
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Bio-Rad Laboratories
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Siemens Healthcare Private Limited
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.10 Thermo Fisher Scientific Inc.
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.10 Beckman Coulter, Inc
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

    • 11.1.1 Related Research